Drug Administration) and EMEA (European Medicines
Agency). This will allow it to operate in new markets
such as in the United States, Europe and Japan. “We
are expanding the production unit of IFAs. Within this
unit we are creating a division devoted to producing
cytostatics. Brazil currently imports 100 percent of
these active cytostatic principles. The other unit is a
pilot biotechnology plant, which will be allocated to the
development of the passing range of second generation
products,” reveals Dr. Pacheco. Also, on opening day
Laboratório de Biotecnologia. Ainda em 2012
o Cristália produzirá insumos biotecnológicos
Visite:
Cristália Produtos Químicos
e Farmacêuticos Ltda.
page 411
September 2012
